In vivo drug-selectable markers in gene therapy

Yoshikazu Sugimoto, Takashi Tsuruo

Research output: Contribution to journalArticle

Abstract

Two-gene vectors with positive or positive-negative drug-selectable markers enable the expansion or elimination of gentetically modified cells in vivo. We have established a bicistronic retroviral vector system which utilizes an internal ribosome entry site (IRES) to co-express two independent genes with high efficiency. As a positive-negative (suicide) marker, Herpes simplex virus thymidine kinase was co-expressed with the human multidrug resistance gene, MDR1. Using this vector, almost all the MDR1-transduced cells showed hypersensitivity to a nucleoside analog, ganciclovir. As a dominant selectable marker, the MDR1 gene was co-expressed with α-galactosidase A for the model of gene therapy of Fabry disease. Vincristine selection efficiently enhanced the population of transduced cells expressing the second non-selectable genes. These drug-selectable retroviral vectors could be applicable to the therapy of many diseases.

Original languageEnglish
Pages (from-to)552-556
Number of pages5
JournalLeukemia
Volume11
Issue numberSUPPL. 3
Publication statusPublished - 1997 Jan 1
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Sugimoto, Y., & Tsuruo, T. (1997). In vivo drug-selectable markers in gene therapy. Leukemia, 11(SUPPL. 3), 552-556.